{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:24:56Z","timestamp":1793381096978,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K23 NS107646-04"],"award-info":[{"award-number":["K23 NS107646-04"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Philanthropic donation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40263-022-00921-5","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T07:05:41Z","timestamp":1653721541000},"page":"591-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment"],"prefix":"10.1007","volume":"36","author":[{"given":"William","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6719-6368","authenticated-orcid":false,"given":"Isabel","family":"Haviland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-4167","authenticated-orcid":false,"given":"Elia","family":"Pestana-Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith L.","family":"Weisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Demarest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5385-0119","authenticated-orcid":false,"given":"Heather E.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,28]]},"reference":[{"issue":"6","key":"921_CR1","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1086\/426460","volume":"75","author":"J Tao","year":"2004","unstructured":"Tao J, Van Esch H, Hagedorn-Greiwe M, Hoffmann K, Moser B, Raynaud M, et al. Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5\/STK9) gene are associated with severe neurodevelopmental retardation. Am J Hum Genet. 2004;75(6):1149\u201354. https:\/\/doi.org\/10.1086\/426460.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"921_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1086\/426462","volume":"75","author":"LS Weaving","year":"2004","unstructured":"Weaving LS, Christodoulou J, Williamson SL, Friend KL, McKenzie OL, Archer H, et al. Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am J Hum Genet. 2004;75(6):1079\u201393. https:\/\/doi.org\/10.1086\/426462.","journal-title":"Am J Hum Genet"},{"issue":"Pt 10","key":"921_CR3","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1093\/brain\/awn197","volume":"131","author":"N Bahi-Buisson","year":"2008","unstructured":"Bahi-Buisson N, Nectoux J, Rosas-Vargas H, Milh M, Boddaert N, Girard B, et al. Key clinical features to identify girls with CDKL5 mutations. Brain. 2008;131(Pt 10):2647\u201361. https:\/\/doi.org\/10.1093\/brain\/awn197.","journal-title":"Brain"},{"issue":"3","key":"921_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/ejhg.2012.156","volume":"21","author":"S Fehr","year":"2013","unstructured":"Fehr S, Wilson M, Downs J, Williams S, Murgia A, Sartori S, et al. The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. Eur J Hum Genet. 2013;21(3):266\u201373. https:\/\/doi.org\/10.1038\/ejhg.2012.156.","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"921_CR5","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1086\/375538","volume":"72","author":"VM Kalscheuer","year":"2003","unstructured":"Kalscheuer VM, Tao J, Donnelly A, Hollway G, Schwinger E, Kubart S, et al. Disruption of the serine\/threonine kinase 9 gene causes severe X-linked infantile spasms and mental retardation. Am J Hum Genet. 2003;72(6):1401\u201311. https:\/\/doi.org\/10.1086\/375538.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"921_CR6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ana.25797","volume":"88","author":"C Cutri-French","year":"2020","unstructured":"Cutri-French C, Armstrong D, Saby J, Gorman C, Lane J, Fu C, et al. Comparison of core features in four developmental encephalopathies in the Rett Natural History Study. Ann Neurol. 2020;88(2):396\u2013406. https:\/\/doi.org\/10.1002\/ana.25797.","journal-title":"Ann Neurol"},{"key":"921_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2019.02.015","volume":"97","author":"HE Olson","year":"2019","unstructured":"Olson HE, Demarest ST, Pestana-Knight EM, Swanson LC, Iqbal S, Lal D, et al. Cyclin-dependent kinase-like 5 deficiency disorder: clinical review. Pediatr Neurol. 2019;97:18\u201325. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2019.02.015.","journal-title":"Pediatr Neurol"},{"issue":"1","key":"921_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1866-1955-7-2","volume":"7","author":"S Fehr","year":"2015","unstructured":"Fehr S, Leonard H, Ho G, Williams S, de Klerk N, Forbes D, et al. There is variability in the attainment of developmental milestones in the CDKL5 disorder. J Neurodev Disord. 2015;7(1):2. https:\/\/doi.org\/10.1186\/1866-1955-7-2.","journal-title":"J Neurodev Disord"},{"key":"921_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106521","volume":"169","author":"H Leonard","year":"2021","unstructured":"Leonard H, Junaid M, Wong K, Demarest S, Downs J. Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder. Epilepsy Res. 2021;169: 106521. https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106521.","journal-title":"Epilepsy Res"},{"issue":"4","key":"921_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/gim.2017.114","volume":"20","author":"MB Stosser","year":"2018","unstructured":"Stosser MB, Lindy AS, Butler E, Retterer K, Piccirillo-Stosser CM, Richard G, et al. High frequency of mosaic pathogenic variants in genes causing epilepsy-related neurodevelopmental disorders. Genet Med. 2018;20(4):403\u201310. https:\/\/doi.org\/10.1038\/gim.2017.114.","journal-title":"Genet Med"},{"issue":"6","key":"921_CR11","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/j.1528-1167.2007.01520.x","volume":"49","author":"N Bahi-Buisson","year":"2008","unstructured":"Bahi-Buisson N, Kaminska A, Boddaert N, Rio M, Afenjar A, Gerard M, et al. The three stages of epilepsy in patients with CDKL5 mutations. Epilepsia. 2008;49(6):1027\u201337. https:\/\/doi.org\/10.1111\/j.1528-1167.2007.01520.x.","journal-title":"Epilepsia"},{"issue":"8","key":"921_CR12","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1111\/epi.16285","volume":"60","author":"ST Demarest","year":"2019","unstructured":"Demarest ST, Olson HE, Moss A, Pestana-Knight E, Zhang X, Parikh S, et al. CDKL5 deficiency disorder: relationship between genotype, epilepsy, cortical visual impairment, and development. Epilepsia. 2019;60(8):1733\u201342. https:\/\/doi.org\/10.1111\/epi.16285.","journal-title":"Epilepsia"},{"issue":"21","key":"921_CR13","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1212\/wnl.0000000000003352","volume":"87","author":"S Fehr","year":"2016","unstructured":"Fehr S, Wong K, Chin R, Williams S, de Klerk N, Forbes D, et al. Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder. Neurology. 2016;87(21):2206\u201313. https:\/\/doi.org\/10.1212\/wnl.0000000000003352.","journal-title":"Neurology"},{"issue":"4","key":"921_CR14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.braindev.2020.12.006","volume":"43","author":"Y Kobayashi","year":"2021","unstructured":"Kobayashi Y, Tohyama J, Takahashi Y, Goto T, Haginoya K, Inoue T, et al. Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants. Brain Dev. 2021;43(4):505\u201314. https:\/\/doi.org\/10.1016\/j.braindev.2020.12.006.","journal-title":"Brain Dev"},{"issue":"1","key":"921_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s11689-021-09384-z","volume":"13","author":"HE Olson","year":"2021","unstructured":"Olson HE, Daniels CI, Haviland I, Swanson LC, Greene CA, Denny AMM, et al. Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder. J Neurodev Disord. 2021;13(1):40. https:\/\/doi.org\/10.1186\/s11689-021-09384-z.","journal-title":"J Neurodev Disord"},{"issue":"16","key":"921_CR16","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1212\/WNL.0b013e3182166e58","volume":"76","author":"KM Klein","year":"2011","unstructured":"Klein KM, Yendle SC, Harvey AS, Antony JH, Wallace G, Bienvenu T, et al. A distinctive seizure type in patients with CDKL5 mutations: hypermotor-tonic-spasms sequence. Neurology. 2011;76(16):1436\u20138. https:\/\/doi.org\/10.1212\/WNL.0b013e3182166e58.","journal-title":"Neurology"},{"issue":"4","key":"921_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.braindev.2006.09.001","volume":"29","author":"S Grosso","year":"2007","unstructured":"Grosso S, Brogna A, Bazzotti S, Renieri A, Morgese G, Balestri P. Seizures and electroencephalographic findings in CDKL5 mutations: case report and review. Brain Dev. 2007;29(4):239\u201342. https:\/\/doi.org\/10.1016\/j.braindev.2006.09.001.","journal-title":"Brain Dev"},{"key":"921_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.yebeh.2019.02.013","volume":"94","author":"G Melikishvili","year":"2019","unstructured":"Melikishvili G, Epitashvili N, Tabatadze N, Chikvinidze G, Dulac O, Bienvenu T, et al. New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy. Epilepsy Behav. 2019;94:308\u201311. https:\/\/doi.org\/10.1016\/j.yebeh.2019.02.013.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"921_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1469-8749.2010.03889.x","volume":"53","author":"F Melani","year":"2011","unstructured":"Melani F, Mei D, Pisano T, Savasta S, Franzoni E, Ferrari AR, et al. CDKL5 gene-related epileptic encephalopathy: electroclinical findings in the first year of life. Dev Med Child Neurol. 2011;53(4):354\u201360. https:\/\/doi.org\/10.1111\/j.1469-8749.2010.03889.x.","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"921_CR20","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1017\/cjn.2019.29","volume":"46","author":"T Peikes","year":"2019","unstructured":"Peikes T, Hartley JN, Mhanni AA, Greenberg CR, Appendino JP. Reflex seizures in a patient with CDKL5 deficiency disorder. Can J Neurol Sci. 2019;46(4):482\u20135. https:\/\/doi.org\/10.1017\/cjn.2019.29.","journal-title":"Can J Neurol Sci"},{"issue":"5","key":"921_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1684\/epd.2018.0999","volume":"20","author":"R Solazzi","year":"2018","unstructured":"Solazzi R, Fiorini E, Parrini E, Darra F, Dalla Bernardina B, Cantalupo G. Diaper changing-induced reflex seizures in CDKL5-related epilepsy. Epileptic Disord. 2018;20(5):428\u201333. https:\/\/doi.org\/10.1684\/epd.2018.0999.","journal-title":"Epileptic Disord"},{"issue":"5","key":"921_CR22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.braindev.2011.07.004","volume":"34","author":"H Saitsu","year":"2012","unstructured":"Saitsu H, Osaka H, Nishiyama K, Tsurusaki Y, Doi H, Miyake N, et al. A girl with early-onset epileptic encephalopathy associated with microdeletion involving CDKL5. Brain Dev. 2012;34(5):364\u20137. https:\/\/doi.org\/10.1016\/j.braindev.2011.07.004.","journal-title":"Brain Dev"},{"issue":"17","key":"921_CR23","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1212\/wnl.0000000000003685","volume":"88","author":"C Harden","year":"2017","unstructured":"Harden C, Tomson T, Gloss D, Buchhalter J, Cross JH, Donner E, et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors. Rep Guidel Dev Dissem Implement Subcomm Am Acad Neurol Am Epilepsy Soc. 2017;88(17):1674\u201380. https:\/\/doi.org\/10.1212\/wnl.0000000000003685.","journal-title":"Rep Guidel Dev Dissem Implement Subcomm Am Acad Neurol Am Epilepsy Soc"},{"issue":"7","key":"921_CR24","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1365-2990.2012.01292.x","volume":"38","author":"SM Paine","year":"2012","unstructured":"Paine SM, Munot P, Carmichael J, Das K, Weber MA, Prabhakar P, et al. The neuropathological consequences of CDKL5 mutation. Neuropathol Appl Neurobiol. 2012;38(7):744\u20137. https:\/\/doi.org\/10.1111\/j.1365-2990.2012.01292.x.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"4","key":"921_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ana.24596","volume":"79","author":"RD Bagnall","year":"2016","unstructured":"Bagnall RD, Crompton DE, Petrovski S, Lam L, Cutmore C, Garry SI, et al. Exome-based analysis of cardiac arrhythmia, respiratory control, and epilepsy genes in sudden unexpected death in epilepsy. Ann Neurol. 2016;79(4):522\u201334. https:\/\/doi.org\/10.1002\/ana.24596.","journal-title":"Ann Neurol"},{"issue":"4","key":"921_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):512\u201321. https:\/\/doi.org\/10.1111\/epi.13709.","journal-title":"Epilepsia"},{"issue":"1","key":"921_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ejpn.2015.09.001","volume":"20","author":"A M\u00fcller","year":"2016","unstructured":"M\u00fcller A, Helbig I, Jansen C, Bast T, Guerrini R, J\u00e4hn J, et al. Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy. Eur J Paediatr Neurol. 2016;20(1):147\u201351. https:\/\/doi.org\/10.1016\/j.ejpn.2015.09.001.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"921_CR28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/acn3.51316","volume":"8","author":"AT Berg","year":"2021","unstructured":"Berg AT, Mahida S, Poduri A. KCNQ2-DEE: developmental or epileptic encephalopathy? Ann Clin Transl Neurol. 2021;8(3):666\u201376. https:\/\/doi.org\/10.1002\/acn3.51316.","journal-title":"Ann Clin Transl Neurol"},{"key":"921_CR29","unstructured":"Mingorance A, Jaksha A, Smart T, Sherriff L, Valentine J. The Voice of the Patient Report: CDKL5 Deficiency Disorder (CDD). https:\/\/www.cdkl5.com\/pfdd\/: Loulou Foundation; International Foundation for CDKL5 Research; 2019."},{"issue":"2","key":"921_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/ajmg.a.61012","volume":"179","author":"J Tangarorang","year":"2019","unstructured":"Tangarorang J, Leonard H, Epstein A, Downs J. A framework for understanding quality of life domains in individuals with the CDKL5 deficiency disorder. Am J Med Genet A. 2019;179(2):249\u201356. https:\/\/doi.org\/10.1002\/ajmg.a.61012.","journal-title":"Am J Med Genet A"},{"key":"921_CR31","unstructured":"Olson H, Demarest S, Pestana-Knight E, Daniels C, Greene CA, DeLeo M, et al. Infantile spasms in CDKL5 deficiency disorder respond poorly to first line treatments. 145th Annual Meeting of the American Neurological Association; 2020 October 4-9, 2020; Virtual; 2020."},{"issue":"3","key":"921_CR32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/ana.24594","volume":"79","author":"KG Knupp","year":"2016","unstructured":"Knupp KG, Coryell J, Nickels KC, Ryan N, Leister E, Loddenkemper T, et al. Response to treatment in a prospective national infantile spasms cohort. Ann Neurol. 2016;79(3):475\u201384. https:\/\/doi.org\/10.1002\/ana.24594.","journal-title":"Ann Neurol"},{"issue":"3","key":"921_CR33","first-page":"130","volume":"21","author":"S Amin","year":"2017","unstructured":"Amin S, Majumdar A, Mallick A, Patel J, Scatchard R, Partridge C, et al. Caregiver\u2019s perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients. Hippokratia. 2017;21(3):130\u20135.","journal-title":"Hippokratia"},{"key":"921_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107946","volume":"118","author":"A Aledo-Serrano","year":"2021","unstructured":"Aledo-Serrano A, Gomez-Iglesias P, Toledano R, Garcia-Penas JJ, Garcia-Morales I, Anciones C, et al. Sodium channel blockers for the treatment of epilepsy in CDKL5 deficiency disorder: findings from a multicenter cohort. Epilepsy Behav. 2021;118: 107946. https:\/\/doi.org\/10.1016\/j.yebeh.2021.107946.","journal-title":"Epilepsy Behav"},{"key":"921_CR35","doi-asserted-by":"publisher","first-page":"107624","DOI":"10.1016\/j.yebeh.2020.107624","volume":"115","author":"SA Hussain","year":"2021","unstructured":"Hussain SA, Heesch J, Weng J, Rajaraman RR, Numis AL, Sankar R. Potential induction of epileptic spasms by nonselective voltage-gated sodium channel blockade: interaction with etiology. Epilepsy Behavior. 2021;115:107624. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107624.","journal-title":"Epilepsy Behavior"},{"key":"921_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108152","volume":"122","author":"T Dale","year":"2021","unstructured":"Dale T, Downs J, Wong K, Leonard H. The perceived effects of cannabis products in the management of seizures in CDKL5 deficiency disorder. Epilepsy Behav. 2021;122: 108152. https:\/\/doi.org\/10.1016\/j.yebeh.2021.108152.","journal-title":"Epilepsy Behav"},{"issue":"21","key":"921_CR37","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1611618.","journal-title":"N Engl J Med"},{"issue":"20","key":"921_CR38","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome. N Engl J Med. 2018;378(20):1888\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1714631.","journal-title":"N Engl J Med"},{"issue":"8","key":"921_CR39","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug\u2013drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246\u201351. https:\/\/doi.org\/10.1111\/epi.13060.","journal-title":"Epilepsia"},{"issue":"3","key":"921_CR40","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/s1474-4422(15)00379-8","volume":"15","author":"O Devinsky","year":"2016","unstructured":"Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270\u20138. https:\/\/doi.org\/10.1016\/s1474-4422(15)00379-8.","journal-title":"Lancet Neurol"},{"issue":"1","key":"921_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40263-018-0589-2","volume":"33","author":"TT Sands","year":"2019","unstructured":"Sands TT, Rahdari S, Oldham MS, Caminha Nunes E, Tilton N, Cilio MR. Long-term safety, tolerability, and efficacy of cannabidiol in children with refractory epilepsy: results from an Expanded Access Program in the US. CNS Drugs. 2019;33(1):47\u201360. https:\/\/doi.org\/10.1007\/s40263-018-0589-2.","journal-title":"CNS Drugs"},{"key":"921_CR42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","volume":"86","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, et al. Open-label use of highly purified CBD (Epidiolex(R)) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131\u20137. https:\/\/doi.org\/10.1016\/j.yebeh.2018.05.013.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"921_CR43","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.nurt.2006.11.003","volume":"4","author":"V Nohria","year":"2007","unstructured":"Nohria V, Giller E. Ganaxolone. Neurotherapeutics. 2007;4(1):102\u20135. https:\/\/doi.org\/10.1016\/j.nurt.2006.11.003.","journal-title":"Neurotherapeutics"},{"issue":"Suppl 2","key":"921_CR44","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/epi.14481","volume":"59","author":"AO Rossetti","year":"2018","unstructured":"Rossetti AO. Place of neurosteroids in the treatment of status epilepticus. Epilepsia. 2018;59(Suppl 2):216\u20139. https:\/\/doi.org\/10.1111\/epi.14481.","journal-title":"Epilepsia"},{"issue":"4","key":"921_CR45","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/epi.13705","volume":"58","author":"MR Sperling","year":"2017","unstructured":"Sperling MR, Klein P, Tsai J. Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures. Epilepsia. 2017;58(4):558\u201364. https:\/\/doi.org\/10.1111\/epi.13705.","journal-title":"Epilepsia"},{"key":"921_CR46","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1474-4422(22)00077-1","volume":"21","author":"EM Pestana-Knight","year":"2022","unstructured":"Pestana-Knight EM, Amin S, Bahi-Buisson N, Benke TA, Cross JH, Demarest ST, et al. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2022;21:417\u201327.","journal-title":"Lancet Neurol"},{"issue":"12","key":"921_CR47","doi-asserted-by":"publisher","first-page":"e1217","DOI":"10.1212\/wnl.0000000000012511","volume":"97","author":"ZM Grinspan","year":"2021","unstructured":"Grinspan ZM, Knupp KG, Patel AD, Yozawitz EG, Wusthoff CJ, Wirrell E, et al. Comparative effectiveness of initial treatment for infantile spasms in a contemporary US cohort. Neurology. 2021;97(12):e1217\u201328. https:\/\/doi.org\/10.1212\/wnl.0000000000012511.","journal-title":"Neurology"},{"issue":"12","key":"921_CR48","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1111\/epi.13937","volume":"58","author":"ST Demarest","year":"2017","unstructured":"Demarest ST, Shellhaas RA, Gaillard WD, Keator C, Nickels KC, Hussain SA, et al. The impact of hypsarrhythmia on infantile spasms treatment response: observational cohort study from the National Infantile Spasms Consortium. Epilepsia. 2017;58(12):2098\u2013103. https:\/\/doi.org\/10.1111\/epi.13937.","journal-title":"Epilepsia"},{"issue":"6","key":"921_CR49","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/epi.12142","volume":"54","author":"J Suleiman","year":"2013","unstructured":"Suleiman J, Brilot F, Lang B, Vincent A, Dale RC. Autoimmune epilepsy in children: case series and proposed guidelines for identification. Epilepsia. 2013;54(6):1036\u201345. https:\/\/doi.org\/10.1111\/epi.12142.","journal-title":"Epilepsia"},{"issue":"8","key":"921_CR50","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1177\/0883073808331344","volume":"24","author":"KM Forrest","year":"2009","unstructured":"Forrest KM, Young H, Dale RC, Gill DS. Benefit of corticosteroid therapy in Angelman syndrome. J Child Neurol. 2009;24(8):952\u20138. https:\/\/doi.org\/10.1177\/0883073808331344.","journal-title":"J Child Neurol"},{"issue":"6","key":"921_CR51","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.braindev.2020.02.004","volume":"42","author":"JH Na","year":"2020","unstructured":"Na JH, Shin S, Yang D, Kim B, Kim HD, Kim S, et al. Targeted gene panel sequencing in early infantile onset developmental and epileptic encephalopathy. Brain Dev. 2020;42(6):438\u201348. https:\/\/doi.org\/10.1016\/j.braindev.2020.02.004.","journal-title":"Brain Dev"},{"key":"921_CR52","unstructured":"Pestana-Knight EM, Naduvil AM, Sumit P, Zeft A. Clinical response to Oral prednisolone and IVIG in children with CDKL5 mutation. American Epilepsy Society Annual Meeting 2017: Washington, DC; 2017."},{"issue":"8","key":"921_CR53","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/epi.13813","volume":"58","author":"Z Lim","year":"2017","unstructured":"Lim Z, Wong K, Olson HE, Bergin AM, Downs J, Leonard H. Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: experience of >100 patients. Epilepsia. 2017;58(8):1415\u201322. https:\/\/doi.org\/10.1111\/epi.13813.","journal-title":"Epilepsia"},{"key":"921_CR54","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3389\/fneur.2018.00530","volume":"9","author":"A Ko","year":"2018","unstructured":"Ko A, Jung DE, Kim SH, Kang HC, Lee JS, Lee ST, et al. The efficacy of ketogenic diet for specific genetic mutation in developmental and epileptic encephalopathy. Front Neurol. 2018;9:530. https:\/\/doi.org\/10.3389\/fneur.2018.00530.","journal-title":"Front Neurol"},{"key":"921_CR55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.eplepsyres.2018.02.003","volume":"141","author":"A Ko","year":"2018","unstructured":"Ko A, Youn SE, Kim SH, Lee JS, Kim S, Choi JR, et al. Targeted gene panel and genotype-phenotype correlation in children with developmental and epileptic encephalopathy. Epilepsy Res. 2018;141:48\u201355. https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.02.003.","journal-title":"Epilepsy Res"},{"key":"921_CR56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejpn.2021.04.007","volume":"33","author":"B Siri","year":"2021","unstructured":"Siri B, Varesio C, Freri E, Darra F, Gana S, Mei D, et al. CDKL5 deficiency disorder in males: five new variants and review of the literature. Eur J Paediatr Neurol. 2021;33:9\u201320. https:\/\/doi.org\/10.1016\/j.ejpn.2021.04.007.","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"921_CR57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1684\/epd.2018.0959","volume":"20","author":"R Stevelink","year":"2018","unstructured":"Stevelink R, Sanders MW, Tuinman MP, Brilstra EH, Koeleman BP, Jansen FE, et al. Epilepsy surgery for patients with genetic refractory epilepsy: a systematic review. Epileptic Disord. 2018;20(2):99\u2013115. https:\/\/doi.org\/10.1684\/epd.2018.0959.","journal-title":"Epileptic Disord"},{"key":"921_CR58","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eplepsyres.2018.07.013","volume":"146","author":"Z Lim","year":"2018","unstructured":"Lim Z, Wong K, Downs J, Bebbington K, Demarest S, Leonard H. Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder. Epilepsy Res. 2018;146:36\u201340. https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.07.013.","journal-title":"Epilepsy Res"},{"issue":"10","key":"921_CR59","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/sj.ejhg.5201451","volume":"13","author":"JC Evans","year":"2005","unstructured":"Evans JC, Archer HL, Colley JP, Ravn K, Nielsen JB, Kerr A, et al. Early onset seizures and Rett-like features associated with mutations in CDKL5. Eur J Hum Genet. 2005;13(10):1113\u201320. https:\/\/doi.org\/10.1038\/sj.ejhg.5201451.","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"921_CR60","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.braindev.2016.10.007","volume":"39","author":"S Baba","year":"2017","unstructured":"Baba S, Sugawara Y, Moriyama K, Inaji M, Maehara T, Yamamoto T, et al. Amelioration of intractable epilepsy by adjunct vagus nerve stimulation therapy in a girl with a CDKL5 mutation. Brain Dev. 2017;39(4):341\u20134. https:\/\/doi.org\/10.1016\/j.braindev.2016.10.007.","journal-title":"Brain Dev"},{"issue":"2","key":"921_CR61","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1375\/twin.13.2.168","volume":"13","author":"R White","year":"2010","unstructured":"White R, Ho G, Schmidt S, Scheffer IE, Fischer A, Yendle SC, et al. Cyclin-dependent kinase-Like 5 (CDKL5) mutation screening in Rett Syndrome and related disorders. Twin Res Hum Genet. 2010;13(2):168\u201378. https:\/\/doi.org\/10.1375\/twin.13.2.168.","journal-title":"Twin Res Hum Genet"},{"issue":"43","key":"921_CR62","doi-asserted-by":"publisher","first-page":"9031","DOI":"10.1523\/JNEUROSCI.1010-21.2021","volume":"41","author":"S Hao","year":"2021","unstructured":"Hao S, Wang Q, Tang B, Wu Z, Yang T, Tang J. CDKL5 deficiency augments inhibitory input into the dentate gyrus that can be reversed by deep brain stimulation. J Neurosci. 2021;41(43):9031\u201346. https:\/\/doi.org\/10.1523\/JNEUROSCI.1010-21.2021.","journal-title":"J Neurosci"},{"issue":"9","key":"921_CR63","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/nejm199708283370901","volume":"337","author":"HM Connolly","year":"1997","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine\u2013phentermine. N Engl J Med. 1997;337(9):581\u20138. https:\/\/doi.org\/10.1056\/nejm199708283370901.","journal-title":"N Engl J Med"},{"issue":"10216","key":"921_CR64","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/s0140-6736(19)32500-0","volume":"394","author":"L Lagae","year":"2019","unstructured":"Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10216):2243\u201354. https:\/\/doi.org\/10.1016\/s0140-6736(19)32500-0.","journal-title":"Lancet"},{"key":"921_CR65","unstructured":"Knupp KG, Scheffer IE, Ceulemans B, Sullivan J, Nickels KC, Miller I, et al. Efficacy and safety of FINTEPLA (fenfluramine) for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized, double-blind, placebo-controlled clinical trial. American Epilepsy Society Annual Meeting 2020: Seattle, Washington; 2020."},{"issue":"7","key":"921_CR66","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1111\/epi.16923","volume":"62","author":"O Devinsky","year":"2021","unstructured":"Devinsky O, King L, Schwartz D, Conway E, Price D. Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder. Epilepsia. 2021;62(7):e98\u2013102. https:\/\/doi.org\/10.1111\/epi.16923.","journal-title":"Epilepsia"},{"issue":"11","key":"921_CR67","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1111\/epi.16638","volume":"61","author":"WW Lai","year":"2020","unstructured":"Lai WW, Galer BS, Wong PC, Farfel G, Pringsheim M, Keane MG, et al. Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: analysis of an ongoing long-term open-label safety extension study. Epilepsia. 2020;61(11):2386\u201395. https:\/\/doi.org\/10.1111\/epi.16638.","journal-title":"Epilepsia"},{"issue":"3","key":"921_CR68","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","volume":"77","author":"R Nabbout","year":"2020","unstructured":"Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, et al. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77(3):300\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4113.","journal-title":"JAMA Neurol"},{"issue":"1","key":"921_CR69","doi-asserted-by":"publisher","first-page":"17081","DOI":"10.1038\/s41598-020-74036-6","volume":"10","author":"T Nishi","year":"2020","unstructured":"Nishi T, Kondo S, Miyamoto M, Watanabe S, Hasegawa S, Kondo S, et al. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice. Sci Rep. 2020;10(1):17081. https:\/\/doi.org\/10.1038\/s41598-020-74036-6.","journal-title":"Sci Rep"},{"issue":"3","key":"921_CR70","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.bbrc.2014.02.010","volume":"446","author":"N Noguchi","year":"2014","unstructured":"Noguchi N, Saito Y, Urano Y. Diverse functions of 24(S)-hydroxycholesterol in the brain. Biochem Biophys Res Commun. 2014;446(3):692\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2014.02.010.","journal-title":"Biochem Biophys Res Commun"},{"issue":"44","key":"921_CR71","doi-asserted-by":"publisher","first-page":"17290","DOI":"10.1523\/JNEUROSCI.2619-13.2013","volume":"33","author":"SM Paul","year":"2013","unstructured":"Paul SM, Doherty JJ, Robichaud AJ, Belfort GM, Chow BY, Hammond RS, et al. The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-d-aspartate receptors. J Neurosci. 2013;33(44):17290\u2013300. https:\/\/doi.org\/10.1523\/JNEUROSCI.2619-13.2013.","journal-title":"J Neurosci"},{"key":"921_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106646","volume":"174","author":"JJ Halford","year":"2021","unstructured":"Halford JJ, Sperling MR, Arkilo D, Asgharnejad M, Zinger C, Xu R, et al. A phase 1b\/2a study of soticlestat as adjunctive therapy in participants with developmental and\/or epileptic encephalopathies. Epilepsy Res. 2021;174: 106646. https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106646.","journal-title":"Epilepsy Res"},{"issue":"15 Supplement","key":"921_CR73","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1212\/WNL.96.15_supplement.4096","volume":"96","author":"S Demarest","year":"2021","unstructured":"Demarest S, Jeste S, Agarwal N, Arkilo D, Forgacs PB, Asgharnejad M, et al. Efficacy, Safety and Tolerability of Soticlestat (TAK-935\/OV935) as an Adjunctive Therapy in Patients with 15q Duplication Syndrome (Dup15q) or Cyclin-Dependent Kinase-Like 5 Deficiency Disorder (CDD) in a Signal-Finding Phase 2 Study (ARCADE) (4096). Neurology. 2021;96(15 Supplement):4096.","journal-title":"Neurology"},{"issue":"3","key":"921_CR74","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/acn3.51306","volume":"8","author":"O Devinsky","year":"2021","unstructured":"Devinsky O, King L, Bluvstein J, Friedman D. Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder. Ann Clin Transl Neurol. 2021;8(3):639\u201344. https:\/\/doi.org\/10.1002\/acn3.51306.","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"921_CR75","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/brain\/awaa028","volume":"143","author":"Y Gao","year":"2020","unstructured":"Gao Y, Irvine EE, Eleftheriadou I, Naranjo CJ, Hearn-Yeates F, Bosch L, et al. Gene replacement ameliorates deficits in mouse and human models of cyclin-dependent kinase-like 5 disorder. Brain. 2020;143(3):811\u201332. https:\/\/doi.org\/10.1093\/brain\/awaa028.","journal-title":"Brain"},{"issue":"9","key":"921_CR76","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/hmg\/ddy064","volume":"27","author":"S Trazzi","year":"2018","unstructured":"Trazzi S, De Franceschi M, Fuchs C, Bastianini S, Viggiano R, Lupori L, et al. CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder. Hum Mol Genet. 2018;27(9):1572\u201392. https:\/\/doi.org\/10.1093\/hmg\/ddy064.","journal-title":"Hum Mol Genet"},{"key":"921_CR77","doi-asserted-by":"publisher","DOI":"10.1172\/jci143655","author":"B Terzic","year":"2021","unstructured":"Terzic B, Davatolhagh MF, Ho Y, Tang S, Liu Y-T, Xia Z, et al. Temporal manipulation of Cdkl5 reveals essential postdevelopmental functions and reversible CDKL5 deficiency disorder\u2013related deficits. J Clin Investig. 2021. https:\/\/doi.org\/10.1172\/jci143655.","journal-title":"J Clin Investig"},{"issue":"167","key":"921_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107746","volume":"1","author":"C Fuchs","year":"2020","unstructured":"Fuchs C, Gennaccaro L, Ren E, Galvani G, Trazzi S, Medici G, et al. Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder. Neuropharmacology. 2020;1(167): 107746. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107746.","journal-title":"Neuropharmacology"},{"issue":"1","key":"921_CR79","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1038\/s41467-019-10689-w","volume":"10","author":"S Tang","year":"2019","unstructured":"Tang S, Terzic B, Wang IJ, Sarmiento N, Sizov K, Cui Y, et al. Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder. Nat Commun. 2019;10(1):2655. https:\/\/doi.org\/10.1038\/s41467-019-10689-w.","journal-title":"Nat Commun"},{"key":"921_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115950","author":"M Loi","year":"2021","unstructured":"Loi M, Gennaccaro L, Fuchs C, Trazzi S, Medici G, Galvani G, et al. Treatment with a GSK-3beta\/HDAC dual inhibitor restores neuronal survival and maturation in an in vitro and in vivo model of CDKL5 deficiency disorder. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22115950.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"921_CR81","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12974-021-02204-0","volume":"18","author":"G Galvani","year":"2021","unstructured":"Galvani G, Mottolese N, Gennaccaro L, Loi M, Medici G, Tassinari M, et al. Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder. J Neuroinflammation. 2021;18(1):155. https:\/\/doi.org\/10.1186\/s12974-021-02204-0.","journal-title":"J Neuroinflammation"},{"key":"921_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113388","volume":"332","author":"PJ Mulcahey","year":"2020","unstructured":"Mulcahey PJ, Tang S, Takano H, White A, Davila Portillo DR, Kane OM, et al. Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms. Exp Neurol. 2020;332: 113388. https:\/\/doi.org\/10.1016\/j.expneurol.2020.113388.","journal-title":"Exp Neurol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00921-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00921-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T20:56:31Z","timestamp":1727297791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00921-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,28]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["921"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00921-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,28]]},"assertion":[{"value":"10 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review was supported by the National Institute of Neurologic Disorders and Stroke (K23 NS107646-04, principal investigator HEO) and by philanthropic donation for CDD research to support WH\u2019s fellowship in Epilepsy Genetics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"WH and IH have no conflicts of interest that are directly relevant to the content of this article. EPK is on the scientific advisory board of Marinus Pharmaceuticals. JLW has received funding from the International Foundation for CDKL5 Research and is a site principal investigator for Marinus Pharmaceuticals. SD has consulted for Upsher-Smith, Biomarin, Neurogene, Marinus, Tysha, and Ovid Therapeutics; has received funding from the National Institutes of Health, the International Foundation for CDKL5 Research, Project 8P, and Mila's Miracle Foundation; and serves on the advisory board for the nonprofit foundations SLC6A1 Connect, Ring14 USA and FamilieSCN2A. EDM is a site principal investigator for trials for Stoke Therapeutics, GW Pharmaceuticals, Zogenix Pharmaceuticals, Acadia Pharmaceuticals, and Marinus Pharmaceuticals; was previously a consultant for Cilpa Pharmaceuticals and Stoke Therapeutics; has received research support from the National Institutes of Health, the Eagles Autism Foundation, the Penn Orphan Disease center, RettSyndrome.org, the International Foundation for CDKL5 Research, and the LouLou Foundation. HEO has consulted for Marinus Pharmaceuticals, Ovid Therapeutics, Zogenix, and Takeda Pharmaceuticals related to CDKL5 deficiency disorder; and has received clinical research funding from the International Foundation for CDKL5 Research and the LouLou Foundation\/Orphan Disease Center at the University of Pennsylvania.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"WH: Conceptualization, literature search, data analysis\/interpretation, manuscript draft preparation, and critical manuscript revision. IH: Literature search, data analysis\/interpretation, manuscript draft preparation, and critical manuscript revision. EPK, JLW, SD, AND EDM: Data analysis\/interpretation and critical manuscript revision. HEO: Conceptualization, data analysis\/interpretation, manuscript draft preparation, and critical manuscript revision. All authors read and approved the final manuscript and agree to be accountable for this work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}